Anavex Life Sciences (AVXL) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Anavex Reports Fiscal First Quarter 2016 Financial Results
February 8, 2016 7:00 AM ESTNEW YORK, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimers disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three months ended December 31, 2015.
Financial Highlights:
Anavex had cash and cash equivalents of approximately $13.8 million as of December 31, 2015, compared to approximately $15.3 million as at September 30, 2015.Anavex used approximately $1.5 million in net cash during the first three... MoreIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Ongoing Investigation of Anavex Life Sciences Corp. and Urges Investors with Losses in Excess of $250,000 to Contact the Firm
February 5, 2016 7:01 PM ESTLOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC announces it is investigating claims against Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL) concerning... More
